Related Experiment Video
Updated: May 11, 2026
Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals
Published on: January 5, 2016
Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency
Andreas Knudsen1, Holger Jon Møller, Terese L Katzenstein
1Department of Infectious Diseases, Copenhagen University Hospital, Kettegaard Allé 30, Hvidovre 2650, Denmark. andreas.knudsen@hvh.regionh.dk
Background:
Soluble CD163 (sCD163) has been associated with arterial inflammation and non-calcified plaques in human immunodeficiency virus (HIV)-infected individuals and has therefore been suggested as a predictive biomarker of myocardial infarction (MI).
Methods:
We conducted a nested case-control study of 55 cases with first-time MI and 182 controls matched for age, duration of antiretroviral therapy (ART), gender, smoking, and no known cardiovascular disease. All patients had four available plasma samples, 1: Before initiation of antiretroviral therapy (ART), 2: Three months after ART, 3: One year before the case's MI, and 4: The last sample available before the case's MI. We used conditional logistic regression to estimate the association of sCD163 with first-time MI.
Results:
The two groups had similar HIV-parameters and cardiovascular risk factors were equally distributed. There was no significant association between sCD163 and MI neither in samples obtained one year before (OR 1.05, CI 95% 0.85 - 1.29, p = 0.66) nor two months before (OR 1.20, CI 95% 0.98-1.47 p = 0.08).
Conclusion:
sCD163 did not prove to be a useful biomarker for prediction of first-time MI in a HIV-infected population.
